Immunotherapy for MDR-TB (Multi-drug-resistant tuberculosis) its feasibility

Kekkaku

Volumn 74, Issue 6, 1999, Pages 479-491

  Tsuyuguchi, Izuo ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

Cytokines; Immunotherapy; MDR TB

Indexed keywords

CYTOKINE; ETHAMBUTOL; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; ISONIAZID; MINOCYCLINE; OFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC THERAPY; ARTICLE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; EDEMA; FEVER; HUMAN; IMMUNOSTIMULATION; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALAISE; MULTIDRUG RESISTANCE; MYCOBACTERIUM VACCAE; NONHUMAN; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; HUMANS; IMMUNOTHERAPY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0032983992     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Flesch IEA and Kaufmann SHE: Mycobacterial growth inhibition by interferon-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosis. J Immunol. 1987; 84 : 200-206.
2. Jouanguy E, Altare F, Lamhamedi S, et al. : Interferon-γ-receptor deficiency in an infant with fatal Bacille Calmette-Guerin infection. N Engl J Med. 1996; 335 : 1956-1961.
3. Newport MJ, Huxley CM, Huston S, et al.: A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N Engl J Med. 1996; 335 : 1941-1949.
4. + T cell counts have impaired Th1 responses. J Immunol. 1997; 158 : 492-500.
5. Sodhi A, Gong J, Silva C, et al.: Clinical correlates of interferon γ production in patients with tuberculosis. Clin Inf Dis. 1997; 25 : 617-620.
6. Holland SM, Eisenstein MD, Kuhns DB, et al.: Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med. 1994; 330 : 1348-1355.
7. Condos R, Rom WN, and Schluger NW: Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet. 1997; 349 : 1513-1515.
8. Flynn J, Goldstein MM, Triebold KJ, et al. : IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol. 1995; 155 : 2515-2524.
9. Saunders BM, Zhan Y, and Cheers C.: Endogenous interleukin-12 is involved in resistance of mice to Mycobacterium avium complex infection. Inf Immun. 1995; 63 : 4011 -4015.
10. Bermudez LE, Wu M, and Young LS: Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Inf Immun. 1995; 63 : 4099-4104.
11. Denis M: Interleukin-12 (IL-12) augments cytolytic activity of natural killer cells toward Mycobacterium tuberculosis-infected human monocytes. Cell Immunol. 1994; 156 : 529-536.
12. Altare F, Durandy A, Lammas D, et al.: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science. 1998; 280 : 1432-1435.
13. de Jong R, Altare F, Haagen I-A, et al.: Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science. 1998; 280 : 1435-1438.
14. Heinzel FP, Schoenhaut DS, Rerko RM, et al.: Recombinant interleukin 12 cures mice infected with Leishmania major. J Exptl Med. 1993; 177 : 1505-1509.
15. Kobayashi K, Gidoh M, Kai M, et al.: The rational basis of interleukin 12 immunotherapy for established mycobacterial infection in mice. Proceeding 33rd US-Japan Research Conference on Tuberculosis and Leprosy. Osaka, 1998, page 184-188.
16. Lotze MT, Hellerstedt B, Stolinski L, et al. : The role of interleukin 2, interleukin 12, and dendritic cells in cancer therapy. Cancer J Sci Am, Suppl 1. 1997; S109-S114.
17. Cohen J: IL-12 death : explanation and a puzzle. Science. 1995; 270 : 908.
18. Shiratsuchi H, Okuda Y, and Tsuyuguchi I: Recombinant human interleukin-2 reverses in vitro - deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients. Inf Immun. 1987; 55 : 2126-2131.
19. Tsuyuguchi I, and Shiratsuchi H: An analysis of in vitro T cell responsiveness in nontuberculous mycobacterial infection. Chest. 1988; 94 : 822-829.
20. Suzuki K, Matsumoto H, Tsuyuguchi K, et al.: Pretreatment of human monocyte-derived macrophages with IL-2, GM-CSF, or TNF-α can, but IFN-γ cannot augment mycobactericidal activity of rifampicin against intramacrophage replicating M. tuberculosis. Proceeding 33rd US-Japan Conference on Tuberculosis and Leprosy. Osaka, 1998; page 162-166.
21. Toba H, Tsuyuguchi I, Kimura H, et al.: Clinical trial of recombinant human IL-2 in the treatment of Mycobacterium avium complex infection, in From clone to clinic. 1990 ; 227-232. D.J.A. Crommelin and H. Schellekens (eds.), Kluwer Academic Publishers.
22. Johnson BJ, Bekker L-G, Rickman R, et al.: rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis : a comparison of two treatment regimens and placebo. Tuberc Lung Dis. 1998; 78 : 195-203.
23. Tramontana JM, Utaiwan U, Molloy A, et al.: Thalidomide treatment reduces tumor necrosis factor α production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1995; 1 : 384-397.
24. Anacker RL, Barclay WR, Brehmer W, et al.: Effectiveness of cell walls of Mycobacterium bovis strain BCG administered by various routes and in different adjuvants in protecting mice against airborne infection with Mycobacterium tuberculosis strain H37Rv. Amer Rev Respir Dis. 1969; 99 : 242-248.
25. Grange JM.: Immunotherapy : a new strategy for tuberculosis. Respir Med. 1997; 91 : 1-4.
26. Stanford JL, Bahr GM, Rook GAW, et al.: Immunotherapy with Mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle. 1990; 71 : 87-93.
27. Bahr GM, Shaaban MA, Gabriel M, et al.: Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle. 1990; 71 : 259-266.
28. Onyebujoh PC, Abdulmumini T, Robinson S, et al.: Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir Med. 1995; 89 : 199-207.
29. Corlan E, Marica C, Macavel C, et al.: Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 1. Newly-diagnosed pulmonary disease. Respir Med. 1997; 91 : 13-19.
30. Corlan E, Marica C, Macavel C, et al.: Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med. 1997; 91 : 21-29.
31. Orme I. in Review on book "Mycobacteria" ASM News. 1998; 64 : 466.
32. Abou-Zeid C, Gares M-P, Inwald J, et al.: Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium uaccae. Inf Immun. 1997; 65 : 1856-1862.
33. Streeton JA, Desem N, and Jones L.: Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis. 1998; 2 : 443-450.
34. McMurray DN, and Zhang X: Impact of protein deficiency on modulation of T-cell activation by alveolar macrophages in guinea pigs. Tuberc Lung Dis. 1997; 78 : 83-84.
35. Bellamy R, Ruwende C, Phil D, et al.: Variations in the NRAMP1 gene and susceptibility to tuberculosis in west Africans. N Engl J Med. 1998; 338 : 640-644.
36. Valway SE, Sanchez MPC, Shinnick TF, et al.: An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl Med. 1998; 338 : 633-639.
37. National Tuberculosis Institute, Bangalore: Tuberculosis in a rural population of South India : a five-year epidemiological study. Bull World Health Organ. 1974; 51 : 473-488.
38. Welsch, M. C.R.S.B. 143 : 1282, 1949.
39. Linz, R. et al.: C.R.S.B. 145 : 143, 1951.
40. Mitchison DA. 1968 in Recent Advances in Tuberculosis.